New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019


Celgene Corporation, Acceleron Pharma, Sangamo Therapeutics & Agios Pharmaceuticals are expected to present new and updated data on the progress of key ongoing therapies for thalassaemia and sickle cell disease (SCD) in the 61st American Society of Hematology Annual Meeting to take place in Orlando, Florida, 7-10 December 2019.

Data from clinical studies of LentiGlobin™ gene therapy for β-thalassaemia and SCD (Bluebird Bio), Luspatercept for β-thalassaemia (Celgene & Acceleron), ST-400 gene editing therapy for transfusion-dependent β-thalassaemia (TDT) (Sangamo), and the oral PK-R activator Mitapivat (AG-348) for adults with non-transfusion dependent thalassaemia (Agios) will be shared by the companies to show the advances that have been achieved so far in the clinical trial studies.

For more information, check the Press Releases issued by the companies below:

Press Release_ Celgene Press Release_ Bluebird Bio Press Release_ Sangamo Press Release_Agios


Back to top button